Patient Preference and Adherence (Mar 2023)
Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
Abstract
José Ramón González-Juanatey,1 Josep Comín-Colet,2 Domingo Pascual Figal,3 Antoni Bayes-Genis,4 Jose Maria Cepeda,5 José M García-Pinilla,6,7 Antonio García-Quintana,8 Luis Manzano,9 Jose Luis Zamorano10 1Cardiology Department, Hospital Clínico Universitario Santiago de Compostela, Centro de investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Santiago de Compostela, Spain; 2Cardiology Department, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain; 3Cardiology Department, Hospital Virgen de la Arrixaca, University of Murcia, Murcia, Spain; 4Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 5Department of Internal Medicine, Hospital Vega Baja, Orihuela, Alicante, Spain; 6Cardiology Department, Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; 7Department of Medicine and Dermatology, Universidad de Málaga, Málaga, Spain; 8Cardiology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain; 9Department of Internal Medicine, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, Madrid, Spain; 10Cardiology Department, Hospital Universitario Ramón y Cajal, Madrid, SpainCorrespondence: José Ramón González-Juanatey, Email [email protected]: Heart failure (HF) is a progressive condition with periods of apparent stability and repeated worsening HF events. Over time, unless optimization of HF treatment, worsening HF events become more frequent and patients enter into a cycle of recurrent events with high morbidity and mortality. In patients with HF there is an activation of deleterious neurohormonal pathways, such as the renin angiotensin aldosterone system and the sympathetic system, and an inhibition of protective pathways, including natriuretic peptides and guanylate cyclase. Therefore, HF burden can be reduced only through a holistic approach that targets all neurohormonal systems. In this context, vericiguat may play a key role, as it is the only HF drug that activates the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate system. On the other hand, it has been described relevant disparities in the management of HF population. Consequently, it is necessary to homogenize the management of these patients, through an integrated patient-care pathway that should be adapted at the local level. In this context, the development of new technologies (ie, video call, specific platforms, remote control devices, etc.) may be very helpful. In this manuscript, a multidisciplinary group of experts analyzed the current evidence and shared their own experience to provide some recommendations about the therapeutic optimization of patients with recent worsening HF, with a particular focus on vericiguat, and also about how the integrated patient-care pathway should be performed.Keywords: heart failure, worsening heart failure, patient-care pathway, vericiguat
